July 28, 2026 Sweden
Diamyd comments on the future and retogatein
BioStock interviews Diamyd Medical’s CEO, Anders Essen-Möller, about the company’s plans following DIAGNODE-3, focusing on retogatein, the strategic review, and potential future business opportunities.
Read the interview here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.